Danaher Corporation (DHR)
NYSE
Closed
Aug 21, 2026
Day's Range
213.4652 wk Range
160.93Overview - DHR - Danaher Corporation
Key Statistics
Valuation
Enterprise Value
177.36B
P/E (Trailing)
‪39.08‬
P/E (Forward)
‪23.53‬
PEG Ratio
‪0.65‬
Price / Sales (TTM)
‪6.12‬
Price / Book
‪2.92‬
EV / EBITDA
‪22.09‬
Profitability
Gross Margin
‪57.63%‬
Profit Margin
‪15.94%‬
Operating Margin
‪19.77%‬
Return on Assets
‪3.94%‬
Return on Equity
‪7.60%‬
Ownership
Shares Outstanding
702.90M
Float
625.83M
Short % of Shares Outstanding
‪1.91%‬
Held by Insiders
‪10.96%‬
Held by Institutions
‪84.50%‬
Price stats
Beta
‪0.79‬
50-Day Avg
‪195.43‬
200-Day Avg
‪202.97‬
Dividends
Payout Ratio
‪25.67%‬
Frequency
Quarterly
Analyst Consensus
26 analysts
Average price target
‪$ 227.96‬Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - DHR - Danaher Corporation
Peers - DHR - Danaher Corporation
Peer Comparison
Compared with companies in Diagnostics & Research listed on NYSE.
Profile Summary - DHR - Danaher Corporation
About
Danaher Corporation is a leading science and technology company that designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. It operates primarily through three key segments: Biotechnology, which provides tools and services for bioprocessing, genomics, and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
